AbbVie (NYSE: ABBV) will announce its third-quarter 2024 financial results on Wednesday, October 30, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 ...

AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this ...

We recently published a list of 8 Best Inexpensive Stocks To Invest In Now. In this article, we are going to take a look at ...

Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were ...

Office of Prescription Drug Promotion (OPDP) recently sent an Untitled Letter to AbbVie, Inc., regarding a television ad starring Serena Williams for its migraine medicine Ubrelvy. According to the ...

On Friday, AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $194.79 which represents a slight increase of $2.89 or 1.51% from the prior close of $191.9. The stock opened at $192.6 and ...

Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...

The startup will be headed by CEO Ron Renaud, who previously led Cerevel Therapeutics — a developer of drugs for neurological conditions — and oversaw its acquisition by AbbVie in an $8.7 billion deal ...

Billionaire Ken Fisher regularly shares his investing wisdom on his YouTube channel, sharing market insights and lessons he’s ...

Patients with chronic spontaneous urticaria improved early, with benefits lasting through the 52-week follow-up for those who ...